Inventiva Pharma

Our team is ready and eager to see you next week, at #TheLiverMeeting2024 hosted by American Association for the Study of Liver Diseases (AASLD)! Visit us at booth 1445 to learn more about our latest advancements in #MASH and our commitment to advancing liver health. See you there! #AASLD

Liver Awareness Month isn’t just about raising awareness of diseases—it's also about taking action for better liver health. Here are a few ways to keep your liver in top shape: • Maintain a healthy weight. • Eat a balanced diet rich in fruits, vegetables, and whole grains. • Limit alcohol consumption. • Stay physically active. • Get regular health check-ups to monitor your liver function. By making these changes, you’re helping your liver stay healthy and strong. Let’s take this month to commit to better habits! #Octoberis4Livers #LiverAwarenessMonth #LiverCancerAwarenessMonth

#PressRelease: Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH. Learn more: https://lnkd.in/eY6YRZtn $IVA #biotech #NASH #MASH #lanifibranor

🎥✨Merci ON HEALTH pour cette interview avec notre CFO Jean VOLATIER et Marc Ferracci, Ministre délégué chargé de l’industrie. Ils ont évoqué notre récente levée de fonds et nos efforts dans le développement d'un traitement potentiel contre la NASH/MASH, également appelée maladie du soda, qui affecte environ 10 % de la population adulte.  🎥✨ Thank you to ON HEALTH for this interview with our CFO, Jean VOLATIER, and Marc Ferracci, Secretary of Industry. They discussed our recent fundraising and our work on developing a potential treatment for NASH/MASH which affects about 10% of the adult population. Marc Ferracci Jean VOLATIER Frederic Cren #lanifibranor #NASH #Inventiva #Innovation #Santé #MASH

We’re excited to participate to the MOSAIC - Global NASH/MASH Trialist Forum on October 24-25 in Washington, DC, where our CMO, Dr. Michael Cooreman will be presenting. Learn more: https://lnkd.in/gsdHgAcu #MOSAIC2024 #NASH #MASH #lanifibranor #Inventiva

We are excited to share that a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH, has been accepted for presentation at the AASLD The Liver Meeting® 2024 To learn more about our poster presentation, read our release: https://lnkd.in/eY6YRZtn #MASH #TLM2024 #AASLD #biotech #NASH #Lanifibranor

This week we announced a financing deal of up to $410 million to accelerate the advancement of our Phase 3 NATiV3 #MASH trial, focused on #lanifibranor as a potential breakthrough therapy. Read the full press release here: https://lnkd.in/eU25PAcc

✨💶 Une levée de fonds record pour Inventiva Pharma. 🔬 Fondée en 2012 et basée à Daix en Bourgogne, Inventiva Pharma vient de réaliser l'une des plus grandes levées de fonds pour une biotech française grâce à un financement de 348 millions d'euros. 🧪 Ces fonds sont destinés à finaliser son étude clinique de phase 3, appelée NATiV3, sur la MASH (maladie de la stéatose hépatique non alcoolique) et à préparer la commercialisation du lanifibranor, son candidat-médicament phare. Frederic Cren I Pierre Broqua I Jean VOLATIER I Michael Cooreman New Enterprise Associates (NEA) I BVF PARTNERS, L.P I Samsara BioCapital I Andera Partners I Eventide Asset Management #Biotech #Levéedefonds #Euronext

📢🔬 Andera Life Sciences is participating in the up to €𝟯𝟰𝟴𝗺 PIPE financing for Inventiva Pharma, a French clinical-stage biotech listed on Euronext and the Nasdaq.   🔎 Inventiva specializes in developing oral small molecule therapies for metabolic diseases, with a focus on treating patients with metabolic dysfunction-associated steatohepatitis (MASH).   𝘾𝙡𝙞𝙘𝙠 𝙝𝙚𝙧𝙚 𝙩𝙤 𝙧𝙚𝙖𝙙 𝙩𝙝𝙚 𝙥𝙧𝙚𝙨𝙨 𝙧𝙚𝙡𝙚𝙖𝙨𝙚: - EN: https://lnkd.in/epX2Cb3P - FR : https://lnkd.in/eupMeQSe #FrenchTech #lifesciences #thepowerofAnd cc Raphael WISNIEWSKI, Elyes Chouaieb, Yanis Feraoun